Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Vasc Health Risk Manag. 2022 Jul 20;18:555-566. doi: 10.2147/VHRM.S275739. eCollection 2022.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.
前蛋白转化酶枯草溶菌素 9（PCSK9）抑制剂是治疗动脉粥样硬化性心血管疾病的有效药物。这些药物在临床试验中得到了充分研究，支持其降低低密度脂蛋白胆固醇（LDL-C）的疗效，并对心血管结局产生影响。自 2015 年 PCSK9 抑制剂获准上市以来，我们在实际应用这些治疗药物方面也积累了丰富的经验。本文回顾了目前的指南建议、临床试验的疗效和安全性证据以及关于成本效益、处方和依从性的数据。本文重点讨论了单克隆抗体类 PCSK9 抑制剂，同时也涉及了其他正在开发的治疗药物。
